{"organizations": [], "uuid": "9523a5f923d2b2290bfa4f1d5bd037d0f57eb3f6", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.wsj.com", "main_image": "https://si.wsj.net/public/resources/images/BN-XC475_1Xkri_TOP_20180122064920.jpg", "site_section": "http://www.wsj.com/xml/rss/3_7014.xml", "section_title": "WSJ.com: US Business", "url": "https://www.wsj.com/articles/celgene-to-buy-juno-therapeutics-for-9-billion-1516624153", "country": "US", "domain_rank": 387, "title": "Celgene to Buy Juno Therapeutics for $9 Billion", "performance_score": 0, "site": "wsj.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-22T14:29:00.000+02:00", "replies_count": 0, "uuid": "9523a5f923d2b2290bfa4f1d5bd037d0f57eb3f6"}, "author": "Cara Lombardo", "url": "https://www.wsj.com/articles/celgene-to-buy-juno-therapeutics-for-9-billion-1516624153", "ord_in_thread": 0, "title": "Celgene to Buy Juno Therapeutics for $9 Billion", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "juno therapeutics inc.", "sentiment": "negative"}, {"name": "celgene", "sentiment": "negative"}, {"name": "billion celgene corp.", "sentiment": "negative"}, {"name": "wall street journal", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Celgene Corp. on Monday said it agreed to buy Juno Therapeutics Inc. for $87 a share in cash, or about $9 billion, in a move that will expand Celgeneâ€™s portfolio of blood-cancer drugs.\nThe Wall Street Journal reported last week the two companies were in deal talks.\n\nThe deal will add a lymphoma treatment, expected to gain regulatory approval... To Read the Full Story Subscribe Sign In", "external_links": [], "published": "2018-01-22T14:29:00.000+02:00", "crawled": "2018-01-22T16:53:15.005+02:00", "highlightTitle": ""}